Varadarajan Indumathy, Ballen Karen
Department of Medicine, University of Virginia Cancer Center, Charlottesville, VA, United States.
Front Oncol. 2022 Feb 11;12:781479. doi: 10.3389/fonc.2022.781479. eCollection 2022.
T-cell prolymphocytic leukemia (T-PLL) is a rare, aggressive hematologic malignancy with a poor prognosis. Alemtuzumab (Campath) remains the cornerstone for treatment, with an 80% complete response (CR). Hematopoietic stem cell transplant (HSCT) is considered the standard of care as consolidative therapy in eligible patients. However, allogeneic stem cell transplant is also complicated by increased rates of infections from chemotherapy, acute graft-versus-host disease (GVHD), and chronic GVHD. This review aims to report the available literature on the efficacy and complications of consolidative HSCT. It also discusses the importance of patient selection and pre- and post-transplant complications including atypical infections and GVHD.
T 细胞原淋巴细胞白血病（T-PLL）是一种罕见的侵袭性血液系统恶性肿瘤，预后较差。阿仑单抗（Campath）仍是治疗的基石，完全缓解率（CR）达 80%。造血干细胞移植（HSCT）被视为符合条件患者巩固治疗的标准疗法。然而，异基因干细胞移植也因化疗导致的感染率增加、急性移植物抗宿主病（GVHD）和慢性 GVHD 而变得复杂。本综述旨在报告关于巩固性 HSCT 疗效和并发症的现有文献。它还讨论了患者选择以及移植前后并发症（包括非典型感染和 GVHD）的重要性。
